no chance for 6.50 prior to any approval imo. Would probably cap any price rise prior to FDA approval at the height of 2020 adjusted for the share dilution since. Too many have been bitten by CRLs and big losses on this stock, and many would tread cautiously and with smaller bets. A run up to potential approval is definitely on the cards though but I wouldn’t imagine it would be more than 2.
Ann: Change in substantial holding, page-203
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
-0.030(2.29%) |
Mkt cap ! $1.461B | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.35 | $1.28 | $1.677M | 1.289M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 44452 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 23596 | 1 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |